Dixon R, Crews T
Res Commun Chem Pathol Pharmacol. 1977 Nov;18(3):477-86.
A simple and specific 125I-radioimmunoassay (RIA) for the determination of the anticonvulsant agent clonazepam directly in plasma has been developed using a previously reported antiserum to the drug. The 125I-radioligand was prepared by reaction of 3-aminoclonazepam with a commercially available acylating reagent, 125I-N-succinimidyl 3(4-hydroxyphenyl) propionate, of high specific activity (approximately 1500 Ci/mM). The method has a workable range between 5 and 100 ng/ml of clonazepam using a 10 mu1 sample of plasma for analysis, which is satisfactory for routine clinical monitoring. The intra and inter-assay coefficients of variation did not exceed 3 and 9% respectively. Recovery of clonazepam was quantitative when the drug was added to a pool of plasma obtained from subjects who had received a wide variety of other anticonvulsants. Clinical plasma samples from subjects receiving clonazepam chronically were assayed for clonazepam by the new 125I-RIA and a previously reported 3H-RIA. The data was subjected to linear regression analysis which gave a slope, intercept and correlation coefficient of 1,-0.33 ng/ml and 0.994 respectively and demonstrated that the two methods are equivalent. However, the 125I-RIA is more rapid and less costly for routine monitoring than the 3H-RIA.
利用先前报道的针对该药物的抗血清,已开发出一种简单且特异的125I放射免疫分析法(RIA),用于直接测定血浆中的抗惊厥药物氯硝西泮。125I放射性配体是通过3 - 氨基氯硝西泮与市售的高比活度(约1500 Ci/mM)酰化试剂125I - N - 琥珀酰亚胺基3(4 - 羟苯基)丙酸反应制备的。该方法使用10 μl血浆样本进行分析时,氯硝西泮的可行范围为5至100 ng/ml,这对于常规临床监测来说是令人满意的。批内和批间变异系数分别不超过3%和9%。当将氯硝西泮添加到从接受多种其他抗惊厥药物的受试者获得的混合血浆中时,氯硝西泮的回收率是定量的。通过新的125I - RIA和先前报道的3H - RIA对长期接受氯硝西泮治疗的受试者的临床血浆样本进行氯硝西泮测定。对数据进行线性回归分析,得到的斜率、截距和相关系数分别为1、 - 0.33 ng/ml和0.994,表明这两种方法等效。然而,对于常规监测,125I - RIA比3H - RIA更快且成本更低。